Patient Capital Management LLC Sells 56,448 Shares of Precigen, Inc. (NASDAQ:PGEN)

Patient Capital Management LLC trimmed its stake in shares of Precigen, Inc. (NASDAQ:PGEN) by 0.3% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,881,246 shares of the biotechnology company’s stock after selling 56,448 shares during the quarter. Patient Capital Management LLC owned approximately 0.06% of Precigen worth $20,027,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the stock. LexAurum Advisors LLC grew its stake in shares of Precigen by 151.9% during the fourth quarter. LexAurum Advisors LLC now owns 691,544 shares of the biotechnology company’s stock worth $775,000 after buying an additional 417,055 shares during the last quarter. Iridian Asset Management LLC CT boosted its holdings in shares of Precigen by 38.8% during the 4th quarter. Iridian Asset Management LLC CT now owns 5,241,922 shares of the biotechnology company’s stock valued at $5,871,000 after acquiring an additional 1,465,962 shares in the last quarter. Barclays PLC grew its position in Precigen by 190.4% during the 3rd quarter. Barclays PLC now owns 189,353 shares of the biotechnology company’s stock worth $179,000 after acquiring an additional 124,141 shares during the last quarter. Rhumbline Advisers grew its position in Precigen by 7.3% during the 4th quarter. Rhumbline Advisers now owns 197,134 shares of the biotechnology company’s stock worth $221,000 after acquiring an additional 13,338 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in Precigen by 1.6% in the 4th quarter. Geode Capital Management LLC now owns 3,299,851 shares of the biotechnology company’s stock worth $3,696,000 after purchasing an additional 53,343 shares in the last quarter. Institutional investors own 33.51% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the company. JMP Securities restated a “market outperform” rating and set a $5.00 price target on shares of Precigen in a report on Tuesday, January 14th. HC Wainwright reiterated a “buy” rating and set a $6.00 target price on shares of Precigen in a research report on Thursday, March 20th. One equities research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $7.00.

Precigen Stock Down 1.5%

Shares of NASDAQ:PGEN opened at $1.35 on Wednesday. The firm has a market cap of $398.47 million, a P/E ratio of -2.45 and a beta of 1.82. Precigen, Inc. has a 12-month low of $0.65 and a 12-month high of $2.17. The business has a fifty day simple moving average of $1.52 and a 200 day simple moving average of $1.29.

Precigen (NASDAQ:PGEN) last issued its quarterly earnings data on Wednesday, March 19th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.02. Precigen had a negative return on equity of 123.06% and a negative net margin of 3,521.68%. The company had revenue of $1.19 million during the quarter, compared to the consensus estimate of $1.30 million. As a group, equities research analysts expect that Precigen, Inc. will post -0.32 EPS for the current year.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.